Axsome Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Axsome Therapeutics, Inc. on November 26, 2018. The Company is an emerging growth company incorporated in Delaware. The report details the entry into a material definitive agreement regarding a loan amendment and the issuance of unregistered equity securities.
Key Financial Metrics and Agreements
- Loan Amendment: Entered into a First Amendment to the Loan and Security Agreement with Silicon Valley Bank (SVB).
- Term Loan Advance: Established a principal amount of $4,000,000 available through May 31, 2019.
- Interest Rate: Floating rate equal to the greater of (A) 2.00% above the prime rate or (B) 7.25% per annum.
- Maturity: The agreement matures on November 1, 2020.
- Warrant Issuance: Issued warrants to SVB and WestRiver Innovation Lending Fund VIII, L.P. to purchase common stock at an exercise price of $3.06 per share.
- Warrant Terms: Initially exercisable for 7,875 shares per holder; automatically exercisable for an additional 23,625 shares upon the making of the loan advance. Total potential shares per holder: 31,500. Expiration date: November 25, 2025.
Material Changes and Conditions
The $4,000,000 term loan advance is conditioned upon the achievement of a specific clinical milestone. The Company must receive positive data from the Phase 2 clinical trial of AXS-12 for the treatment of narcolepsy, sufficient to submit a Phase 3 protocol to the FDA and proceed to a Phase 3 trial. The filing text does not provide specific revenue, profit, cash flow, or margin figures for this period.
Outlook, Risks, and Contingencies
The primary contingency for accessing the new funding is the successful Phase 2 clinical data for AXS-12. The Company relies on Section 4(a)(2) of the Securities Act of 1933 as an exemption from registration for the warrant issuance, based on the accredited investor status of the holders. The warrants include an automatic exercise provision on a net issuance basis if not exercised prior to expiration and the fair market value exceeds the exercise price.
Key Facts for Investor Verification
- Verify the status of the Phase 2 clinical trial for AXS-12 to determine if the $4,000,000 loan advance condition has been met.
- Review the full text of the Loan Amendment and Warrant forms when filed as exhibits to understand all covenants and dilution risks.
- Monitor the Company's cash position and burn rate given the milestone-dependent nature of the new debt facility.
- Confirm the total number of shares underlying the warrants (31,500 per holder) and the potential dilution impact upon exercise.